# Radiogenomics: predicting radiation sensitivity from genes

Source: https://onco.cc/technologies/radiogenomics/  
OnCo record `radiogenomics` (Technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Using a tumour's gene expression or a patient's inherited variants to predict who needs more dose, who needs less, and who is at risk of severe side effects.

## Summary

Two strands share the name. Tumour radiogenomics builds signatures such as the radiosensitivity index and the genomic-adjusted radiation dose that estimate how sensitive a tumour is and propose a personalised dose; prospective trials are beginning to test dose adjustment on these scores. Patient radiogenomics looks for inherited variants that predict normal-tissue toxicity, through consortia such as REQUITE and the Radiogenomics Consortium; effect sizes have been modest so far. Both aim to replace one-dose-fits-all prescriptions with dose tailored to biology.

## Fields

- Kind: Technology
- Status: emerging
- Last checked: 2026-09-16
- Tags: radiation-wave1
- Principle: Gene expression or germline variants correlate with tumour or normal-tissue radiosensitivity and can guide dose prescription.
- Since: 2009
- Strengths: Path to personalised dose; Uses existing sequencing; Large consortia data
- Limitations: Prospective validation still limited; Small effect sizes for toxicity variants; Signatures differ across cancers

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Radiogenomics

## Connected records

- fronts: [Radiation Therapy](https://onco.cc/fronts/radiation/)
- technologies: [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [Radiomics](https://onco.cc/technologies/radiomics/)
- terms: [Alpha/beta ratio](https://onco.cc/terms/alpha-beta-ratio/)

---
JSON: https://onco.cc/api/v1/entities/radiogenomics.json